Personalis Announces Expansion of Scientific and Clinical Team: Deanna Church and Robert Nussbaum

DNA

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc., the leading provider of advanced medical exome and genome sequencing and interpretation services today announced that Deanna Church, Ph.D., has joined its R&D team, and Robert Nussbaum, M.D., Professor of Medicine and Chief of the Division of Genomic Medicine at UCSF, has joined its Clinical and Scientific Advisory Board. Dr. Nussbaum will bring his deep expertise in medical genetics to guide development of Personalis' next-generation sequencing (NGS) based clinical services. Dr. Church comes to Personalis from the NCBI where she helped lead development of the newest Human Reference GRCh38 as well as genomic tools used by scientists worldwide. "We are thrilled that both Dr. Nussbaum and Dr. Church are joining our team," said Personalis Chief Scientific Officer Richard Chen, M.D. "Dr. Nussbaum brings world class expertise to our clinical product development while Dr. Church's deep expertise on the structure of the human genome, scientific tools and databases will help us continue to advance our application of NGS data to research and clinical use."

"We are dedicated to pushing the envelope of accuracy, completeness and clinical utility in human genomic analysis, and Drs. Church and Nussbaum both share our vision and will be instrumental in helping us to advance it"
"We are dedicated to pushing the envelope of accuracy, completeness and clinical utility in human genomic analysis, and Drs. Church and Nussbaum both share our vision and will be instrumental in helping us to advance it," added Personalis CEO John West.

About Personalis

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Personalis provides researchers and clinicians accurate DNA sequencing and interpretation of human exomes and genomes. We support researchers engaging in case-control, family-based, or proband-only genomic studies of disease, pharmacogenomics, and cancer. Our ACE (Accuracy and Content Enhanced) Technology™ supplements a standard exome or genome, substantially increasing its medically-relevant coverage and accuracy. Personalis builds on this enhanced sequencing foundation with innovative algorithms and proprietary databases for alignment, variant calling, annotation, and analysis. Through this comprehensive approach, we provide genomic data and interpretation of the highest accuracy.

Contacts

Personalis, Inc.
Carol Tillis, 1-650-752-1300
[email protected]
www.personalis.com

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.